Novo Holdings is repositioning the strategic focus of its REPAIR Fund in order to provide later-stage support to its portfolio companies, as the struggling antibiotics industry faces a dearth of investment.

The Danish investor launched its REPAIR Impact Fund in 2018. An acronym for “Replenishing and Enabling the Pipeline for Anti-Infective Resistance,” the fund has invested a total of $48 million across eight companies based in the US and Europe to date—including $12 million this week.

The first of these investments was $3.9 million to Integrated Biotherapeutics’ subsidiary, IBT Vaccines, which is developing a vaccine for staph infections. The fund also… Read more »

UNDERWRITERS AND PARTNERS